Suppr超能文献

林奇综合征(遗传性非息肉病性结直肠癌)与子宫内膜癌。

Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma.

作者信息

Garg K, Soslow R A

机构信息

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York 10065, USA.

出版信息

J Clin Pathol. 2009 Aug;62(8):679-84. doi: 10.1136/jcp.2009.064949.

Abstract

Women with hereditary non-polyposis colorectal cancer (HNPCC)/Lynch syndrome have a high risk for endometrial cancer (EC) and frequently present with a gynaecological cancer as their first or sentinel malignancy. Identification of these patients is important given their personal and family risk for synchronous and metachronous tumours. Modalities to detect ECs for the possibility of HNPCC include microsatellite instability assay, immunohistochemistry for DNA mismatch repair proteins, MLH1 promoter hypermethylation assay and mutational analysis of DNA mismatch repair genes. The revised Bethesda guidelines provide screening criteria for HNPCC in colorectal cancers (CRCs). However, there are currently no such screening recommendations for women with endometrial carcinoma. While age and family history are useful screening criteria, their sensitivity has been shown to be low for detection of HNPCC in EC. Expansion of these criteria to include tumour morphology (presence of tumour infiltrating lymphocytes and tumour heterogeneity including dedifferentiated/undifferentiated ECs) and topography (lower uterine segment localisation) as well as presence of synchronous ovarian clear cell carcinomas may significantly enhance the detection of patients with EC at risk for HNPCC. Consideration should be given to incorporating these screening criteria into a revision of the Bethesda guidelines for detecting EC patients at highest risk for HNPCC.

摘要

患有遗传性非息肉病性结直肠癌(HNPCC)/林奇综合征的女性患子宫内膜癌(EC)的风险很高,并且常以妇科癌症作为首发或哨兵恶性肿瘤。鉴于这些患者发生同步和异时性肿瘤的个人及家族风险,识别这些患者很重要。用于检测可能患有HNPCC的EC的方法包括微卫星不稳定性检测、DNA错配修复蛋白的免疫组织化学检测、MLH1启动子高甲基化检测以及DNA错配修复基因的突变分析。修订后的贝塞斯达指南提供了结直肠癌(CRC)中HNPCC的筛查标准。然而,目前对于患有子宫内膜癌的女性尚无此类筛查建议。虽然年龄和家族史是有用的筛查标准,但已表明它们在检测EC中的HNPCC时敏感性较低。将这些标准扩展到包括肿瘤形态(肿瘤浸润淋巴细胞的存在以及肿瘤异质性,包括去分化/未分化的EC)和部位(子宫下段定位)以及同步性卵巢透明细胞癌的存在,可能会显著提高对有HNPCC风险的EC患者的检测率。应考虑将这些筛查标准纳入贝塞斯达指南的修订版中,以检测HNPCC风险最高的EC患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验